治疗前血红蛋白水平是肺腺癌患者的独立预后因素。
Pretreatment Hemoglobin Level Is an Independent Prognostic Factor in Patients with Lung Adenocarcinoma.
作者信息
Zhang Yue-Hua, Lu Yuquan, Lu Hong, Zhang Meng-Wei, Zhou Yue-Min, Li Xiang-Lei
机构信息
Department of Oncology, Huaihe Hospital of Henan University, Kaifeng 475001, China.
Department of Oncology, The First Affiliated Hospital of Henan University, Kaifeng 475001, China.
出版信息
Can Respir J. 2018 May 15;2018:6328127. doi: 10.1155/2018/6328127. eCollection 2018.
BACKGROUND/AIM: Few studies have reported the prognostic value of pretreatment hemoglobin levels in patients with lung adenocarcinoma (LA). In the present study, we retrospectively reviewed 306 LA patients for their prognosis associated with the pretreatment hemoglobin levels.
METHODS
Person-years and case fatality rate (CFR) were calculated from May 2010 to June 2017. Hazard ratio (HR) and 95% confidence intervals (CIs) were estimated using the Cox proportional hazards regression analysis. Survival curves were generated using the Kaplan-Meier analysis.
RESULTS
Patients with low pretreatment hemoglobin (LPHb) levels had a higher CFR than did patients with normal pretreatment hemoglobin (NPHb) levels (HR = 1.48, 95% CI = 1.06-2.08, and =0.023). Overall survival of NPHb patients was significantly higher than that of LPHb patients ( < 0.05).
CONCLUSION
Low pretreatment hemoglobin level was demonstrated to be an independent biomarker for poor prognosis in patients with LA.
背景/目的：很少有研究报道肺腺癌（LA）患者治疗前血红蛋白水平的预后价值。在本研究中，我们回顾性分析了306例LA患者，以探讨治疗前血红蛋白水平与预后的关系。
方法
计算2010年5月至2017年6月的人年数和病死率（CFR）。采用Cox比例风险回归分析估计风险比（HR）和95%置信区间（CI）。使用Kaplan-Meier分析生成生存曲线。
结果
治疗前血红蛋白水平低（LPHb）的患者病死率高于治疗前血红蛋白水平正常（NPHb）的患者（HR = 1.48，95% CI = 1.06 - 2.08，P = 0.023）。NPHb患者的总生存率显著高于LPHb患者（P < 0.05）。
结论
治疗前血红蛋白水平低被证明是LA患者预后不良的独立生物标志物。
Zotero 插件